Danazol in treatment of lupus thrombocytopenia.

KY Wong
In: Asian Pacific journal of allergy and immunology · 1991 · vol. 9(2) , pp. 125–9 · PMID:1807260 · W1553133651
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Danazol treatment of seven patients with lupus-associated thrombocytopenia resulted in complete responses in four patients, with improvement in other SLE manifestations and minimal side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Seven patients with systemic lupus erythematosus (SLE), persistent thrombocytopenia (TP), in whom it was considered undesirable to institute an increase in steroid or immunosuppressive agents, were treated with danazol. Five patients completed the minimum period of 8 weeks. Two patients showed early response to danazol but were switched over to cyclophosphamide or azathioprine after 4 weeks because of systemic disease. Of the remaining five patients, four had complete responses. In one patient who failed treatment the TP was considered to be related to another drug (ranitidine). Other manifestations of SLE also improved with treatment. Side effects included amenorrhea in one patient, and hypoglycemia and hyponatremia in another. Infections were absent. Danazol can be a useful alternative treatment of lupus TP.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

Cited by (2)

References (10)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-11T03:23:35.768659+00:00
License: CC0 · commercial use OK